Understanding the Market | ASCLETIS-B rises over 3% and will announce early research results of obesity candidate drug ASC47
ASCLETIS-B's stock price rose over 3%, currently reported at HKD 6.55, with a trading volume of HKD 7.4352 million. The company will report early research results of its obesity candidate drug ASC47 at the 32nd European Congress on Obesity. ASC47 has been approved by the FDA for clinical trials, and there are rumors that the World Health Organization will include weight loss drugs in its essential medicines list. CITIC Securities expects the weight loss drug sector to welcome a thematic market
According to Zhitong Finance APP, ASCLETIS-B (01672) rose over 3%, up 3.48% to HKD 6.55 as of the time of writing, with a trading volume of HKD 7.4352 million.
In terms of news, ASCLETIS recently announced that it will present early research on its obesity candidate drug ASC47, which targets fat and promotes weight loss without muscle loss, in both oral and poster formats at the 32nd European Congress on Obesity (ECO 2025) to be held in Malaga, Spain. It is reported that ASC47 is a thyroid hormone receptor β (THRβ) selective small molecule agonist developed independently by ASCLETIS, designed for fat targeting and ultra-long-acting subcutaneous (SQ) injection. The U.S. Food and Drug Administration (FDA) has approved the new drug clinical trial application for ASC47 in combination with semaglutide for the treatment of obesity.
Additionally, there are rumors that "the World Health Organization plans to include weight loss drugs in the essential medicines list for the treatment of adult obesity for the first time." On May 7, the World Health Organization officially responded that guidelines for treating adult obesity patients are being comprehensively developed according to the procedures of the guideline review committee, with the final plan expected to be released in August or September 2025. CITIC Securities previously indicated that it expects subsequent performance guidance from overseas giants and strong drug sales data to exceed expectations, along with the disclosure of phased results from the development of overseas GLP-1 drugs for other indications and the successful approval of domestic related products, which will repeatedly catalyze the weight loss drug sector and is expected to form a cross-year thematic market
